The role of oxidative stress in the pathogenesis of multiple sclerosis: Current State

Oxidative Stress and Neurodegenerative Disorders

Volumn , Issue , 2007, Pages 283-295

  Lev, Nirit ^a   Gilgun Sherki, Yossi ^a   Offen, Daniel ^a   Melamed, Eldad ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77649237362     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-044452809-4/50154-X     Document Type: Chapter

References (93)

1. JH Noseworthy, C Lucchinetti, M Rodriguez, et al. (2000) Multiple sclerosis. N Eng J Med 343 938-952.
2. C Jersild, T Fog and GS Hansen (1973) On the causes of multiple sclerosis. Med Hypothesis 41 93-96.
3. BD Trapp, R Ransohoff and R Rudick (1999) Axonal pathology in multiple sclerosis: relationship to neurologic disability. Curr Opin Neurol 12 295-302.
4. N Evangelou, M Jackson, D Beeson, et al. (1999) Association of the APOE epsilon 4 allele with disease activity in multiple sclerosis. J Neurol Neurosurg Psychiatry 67 203-205.
5. KM Myhr, G Raknes, H Nyland, et al. (1999) Immunoglobulin G Fc receptor (Fc gamma R) IIA and IIIB polymorphisms related to disability in MS. Neurology 52 1771-1776.
6. AD Sadovnick, H Armstrong, GP Rice, et al. (1993) A population-based study of multiple sclerosis in twins: update. Ann Neurol 33 281-285.
7. HM Schrijver, JB Crusius, BM Uitdehaag, et al. (1999) Association of interleukin-1 beta and interleukin-1 receptor antagonist genes with diseases severity in MS. Neurology 52 595-599.
8. P Stinissen, J Raus and J Zhang (1997) Autoimmune pathogenesis of multiple sclerosis: role of autoreactive T.lymphocytes and new immunotherapeutic strategies. Critic Rev in Immunol 17 33-75.
9. R Egg, M Reindl, F Deisenhammer, et al. (2001) Anti-MOG and anti-MBP antibody subclasses in multiple sclerosis. Mult Scler 5 285-289.
10. S.N. De Stefano N, S Naroyoanan, PM Matthews, et al. (1999) In vivo evidence for axonal dysfunction remote from focal cerebral demyelination of the type seen in multiple sclerosis. Brain 122 1933-1939.
11. B Ferguson, MK Matyszak and MM Esivi (1997) Axonal damage in acute multiple sclerosis lesions. Brain 120 292-399.
12. E Silber and MK Sharief (1999) Axonal degeneration in the pathogenesis of multiple sclerosis. J Neurol Sci 170 11-18.
13. BD Trapp, J Peterson, RM Ransohoff, et al. (1998) Axonal transection in the lesions of multiple sclerosis. N Engl J Med 338 278-285.
14. Y Gilgun-Sherki, E Melamed and D Offen (2001) Oxidative stress induced-neurodegenerative diseases: the need for antioxidants that penetrate the blood brain barrier. Neuropharmacology 40 959-975.
15. R Brett and MG Rumsby (1993) Evidence of free radical damage in the central nervous system of guinea-pigs at the prolonged acute and early relapse stages of chronic relapsing experimental. Neurochem Int 23 35-44.
16. EN Benveniste (1997) Role of macrophages/microglia in multiple sclerosis and experimental allergic encephalomyelitis. J Mol Med 75 165-173.
17. CF Brosnan and CS Raine (1996) Mechanisms of immune injury in multiple sclerosis. Brain Pathol 6 243-257.
18. RN Saha and K Pahan (2003) TNF-alpha at the crossroad of neuronal life and death during HIV-associated dementia: a review. J Neurochem 86 1057-1071.
19. M Jana and K Pahan (2005) Redox regulation of cytokine-mediated inhibition of myelin gene expression in human primary oligodendrocytes. Free Radical Biol Med 39 823-831.
20. TM Dawson, M Sasaki, M Gonzalez-Zulueta, et al. (1998) Regulation of neuronal nitric oxide synthase and identification of novel nitric oxide signaling pathways. Prog Brain Res 118 3-11.
21. J Li, O Baud, T Vartanian, JJ Volpe, et al. (2005) Peroxynitrite generated by inducible nitric oxide syn-thase and NADPH oxidase mediates microglial toxicity to oligodendrocytes. Proc Natl Acad Sci USA 102 9936-9941.
22. D Leppert, E Waubant and R. Galardy R et al (1995) T cell gelatinases mediate basement membrane transmigration. in vitro. J Immunol 154 4379-4389.
23. AM Romanic and JA Madri (1994) Extracellular matrix-degrading proteinases in the nervous system. Brain Pathol 4 145-156.
24. AK Cross, G Haddock, J Surr, et al. (2006) Differential expression of ADAMTS-1,-4,-5 and TIMP-3 in rat spinal cord at different stages of acute experimental autoimmune encephalomyelitis. J Autoimm 26 16-23.
25. HP Hartung and BC Kieseir (2000) The role of matrix metalloproteinases in autoimmune damage to the central and peripheral nervous system. J Neuroimmunol 107 140-147.
26. RLP Lindberg, G.C.J.A. De Groot CJA, et al. (2001) The expression profile of matrix metalloproteinases (MMPs) and their inhibitors (TIMPs) in lesions and normal appearing white matter of multiple sclerosis. Brain 124 1743-1753.
27. EH Lo, X Wang and ML Cuzner (2002) Extracellular proteolysis in brain injury and inflammation: role for plasminogen activators and matrix metalloproteinases. J Neurosci Res 69 1-9.
28. GA Rosenberg (2002) Matrix metalloproteinases in neuroinflammation. Glia 39 279-291.
29. D Offen, Y Gilgun-Sherki, Y Brahum, et al. (2004) A low molecular weight copper chelator crosses the blood-brain barrier and attenuates experimental autoimmune encephalomyelitis. J Neurochem 89 1241-1251.
30. JW McDonald, SP Althomsons, KL Hyrc, et al. (1998) Oligodendrocytes from forebrain are highly vulnerable to AMPA/kainite receptor-mediated excitotoxicity. Nat Med 4 291-297.
31. C Matute, MV Sanchez-Gomez, L Martinez-Millan, et al. (1997) Glutamate receptor-mediated toxicity in optic nerve oligodendrocytes. Proc Natl Acad Sci USA 94 8830-8835.
32. N Burnashev (1996) Calcium permeability of glutamate gated channels in the central nervous system. Curr Opin Neurobiol 6 311-317.
33. C Matute (1998) Characteristics of acute and chronic kainate excitotoxic damage to the optic nerve. Proc Natl Acad Sci USA 95 10229-10234.
34. D Pitt, P Werner and CS Raine (2000) Glutamate excitotoxicity in a model of multiple sclerosis. Nat Med 6 67-70.
35. T Smith, A Groom, B Zhu, et al. (2000) Autoimmune encephalomyelitis ameliorated by AMPA antagonists. Nat Med 6 62-66.
36. L Bo, T Dawson, S Wesselingh, et al. (1994) Induction of nitric oxide synthase in demyelinating regions of multiple sclerosis brains. Ann Neurol 36 778-786.
37. H Koprowski, YM Zheng, E Heber-Katz, et al. (1993) Histocompatibility determinants in multiple sclerosis, with special reference to clinical course. Lancet 2 1121-1125.
38. A Van der Goes, J Brouwer, K Hoekstra, et al. (1998) Reactive oxygen species are required for the phagocytosis of myelin by macrophages. J Neuroimmunol 92 67-75.
39. J Barnes and M Karin (1997) Nuclear factor kappa B-a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 336 1066-1071.
40. PG Winyard and DR Blake (1997) Antioxidants, redox-regulated transcription factors, and inflammation. H Sies,(Ed.) Antioxi- dants in disease mechanisms and therapy. Advances in pharmacology San Diego: Academic press 403-421.
41. SR Ruuls, J Bauer, K Sontrop, et al. (1995) Reactive oxygen species are involved in the pathogenesis of experimental allergic encephalomyelitis in Lewis rats. J Neuroimmunol 56 207-217.
42. TM Kauppinen, SW Suh, CP Genain, et al. (2005) Poly (ADP-ribose) polymerase-1 activation in a primate model of multiple sclerosis. J Neurosci Res 81 190-198.
43. C Espejo, M Penkowa, I Saez-Torres, et al. (2002) Interferon-gamma regulates oxidative stress during experimental autoimmune encephalomyelitis. Exp Neurol 177 21-31.
44. M Penkowa, C Espejo, EM Martinez-Caceres, et al. (2003) Increased demyelination and axonal damage in metal-lothionein I+II-deficient mice during experimental autoimmune encephalomyelitis. Cell Mol Life Sci 60 185-197.
45. C Espejo, M Penkowa, M Demestre, et al. (2005) Time-course expression of CNS inflammatory, neurodegen-erative tissue repair markers and metallothioneins during experimental autoimmune encephalomyelitis. Neuroscience 132 1135-1149.
46. MIS Hunter, S Nledmadin and DLW Davidson (1985) Lipid peroxidation produces and antioxidants proteins in plasma and cerebrospinal fluid from multiple sclerosis patients. Neurochem Res 10 1645-1652.
47. R Naidoo and ML Knapp (1992) Studies of lipid peroxidation products in cerebrospinal fluid and serum in multiple sclerosis and other conditions. Clin Chem 38 2449-2454.
48. SM LeVine (1992) The role of reactive oxygen species in the pathogenesis of multiple sclerosis. Med Hypotheses 39 271-274.
49. JS Liu, ML Zhao, CF Brosnan, et al. (2001) Expression of inducible nitric oxide synthetase and nitrotyrosine in multiple sclerosis lesions. Am J Pathol 158 2057-2066.
50. OA Bizzozero, G DeJesus, K Callahan, et al. (2005) Elevated protein carbonylation in the brain white matter and grey matter of patients with Multiple Sclerosis. J Neurosc Res 81 687-695.
51. E Karg, P Klivenyi, RE Nemeth, et al. (1999) Nonenzymatic antioxidants of blood in multiple sclerosis. J Neurol 246 533-539.
52. T Zagorski, I Dudek, L Berkan, et al. (1991) Superoxide dismutase (SOD-1) activity in erythrocytes of patients with multiple sclerosis. Neurol Neurochir Pol 25 725-730.
53. I Dudek, T Zagorski, J Liskiewicz, et al. (1992) Effect of gamma radiation on selected indicators of oxygen metabolism in erythrocytes of patients with multiple sclerosis. Neurol Neurochir Pol 26 34-39.
54. C Syburra and S Passi (1999) Oxidative stress in patients with multiple sclerosis. Ukr Biokhim Zh 71 112-115.
55. A Greco, L Minghetti, G Sette, et al. (1999) Cerebrospinal fluid isoprostane shows oxidative stress in patients with multiple sclerosis. Neurology 53 1876-1879.
56. V Calabrese, R Raggaele, E Cosentino, et al. (1994) Changes in cerebrospinal fluid levels of malondialdehyde and glutathione reductase activity in multiple sclerosis. Int J Clin Pharacol Res 14 119-123.
57. M Koch, GS Ramsaransing, AV Arutjunyan, et al. (2006) Oxidative stress in serum and peripheral blood leukocytes in patients with different disease courses of multiple sclerosis. J Neurol 253 483-487.
58. M Lucas, MC Rodriguez, JM Gata, et al. (2003) Regulation by interferon beta-1a of reactive oxygen metabolites production by lymphocytes and monocytes and serum sulfhydryls in relapsing multiple sclerosis. Neurochem Int 42 67-71.
59. G Ferretti, D.L.F. BacchettiT DiLudovico F, et al. (2006) Intracellular oxidative activity and respiratory burst of leukocytes isolated from multiple sclerosis patients. Neurochem Int 48 87-92.
60. H Langemann, A Kabiersch and J Newcombe (1992) Measurement of low-molecular-weight antioxidants, uric acid, tyrosine and tryptophan in plaques and white matter from patients with multiple sclerosis. Eur Neurol 32 248-252.
61. O Vladimirova, J O'Connor, A Cahill, et al. (1998) Oxygen damage to DNA in plaques of MS brains. Multiple Sclerosis 4 413-418.
62. O Vladimirova, FM Lu, L Shawver, et al. (1999) The activation of protein kinase C induces higher production of reactive oxygen species by mononuclear cells in patients with multiple sclerosis than in contr. Inflamm Res 48 412-416.
63. FM Lu, M Selak, J O'Connor, et al. (2000) oxidative damage to mitochondrial DNA and activity of mitochondrial enzymes in chronic lesions of multiple sclerosis. J Neurolo Sci 177 95-103.
64. JF Stover, UE Pleines, MC Morganti-Kossmann, et al. (1997) Neurotransmitters in cerebrospinal fluid reflect pathological activity. Eur J Clin Invest 27 1038-1043.
65. VP Barkhatova, IA Zavalishin, LS Askarova, et al. (1998) Changes in neurotransmitters in multiple sclerosis. Neurosci. Behav Physiol 28 341-344.
66. P Werner, D Pitt and CS Raine (2001) Multiple sclerosis: altered glutamate homeostasis in lesions correlates with oligodendrocyte and axonal damage. Ann Neurol 50 169-180.
67. JM Antony, M.G. van Marle G, W Opii, et al. (2004) Human endogenous retrovirus glycoprotein-mediated induction of redox reactants causes oligodendrocytes death and demyelination. Nat Neurosc 7 1088-1095.
68. D Lehmann, D Karussis, R Misrachi-Koll, et al. (1994) Oral administration of the oxidant-scavenger N-acetyl-L-cysteine inhibits acute experimental autoimmune encephalomyelitis. J Neuroimmunol 50 35-42.
69. Y Gilgun-Sherki, Y Barhum, D Atlas, et al. (2005) Analysis of gene expression in MOG-induced experimental autoimmune encephalomyelitis after treatment with a novel brain-penetrating antioxidant. J Mol Neurosci 27 125-135.
70. M Bahat-Stroomza, Y Gilgun-Sherki, D Offen, et al. (2005) A novel thiol antioxidant that crosses the blood brain barrier protects dopaminergic neurons in experimental models of Parkinson's disease. Eur J Neurosci 21 637-646.
71. O Sadan, M Bahat-Stromza, Y Gilgun-Sherki, et al. (2005) A novel brain-targeted antioxidant (AD4) attenuates haloperidol-induced abnormal movement in rats: implications for tardive dyskinesia. Clin Neuropharmacol 28 285-288.
72. GH Marracci, RE Jones, GP McKeon, et al. (2002) Alpha lipoic acid inhibits T cell migration into the spinal cord and suppresses and treats experimental autoimmune encephalomyelitis. J Neuroimmunol 13 104-114.
73. M Morini, L Roccatagliata, R Dell'Eva, et al. (2004) Alpha-lipoic acid is effective in prevention and treatment of experimental autoimmune encephalomyelitis. J Neuroimmunol 148 146-153.
74. DC Hooper, O Bagasra, JC Marini, et al. (1997) Prevention of experimental allergic encephalomyelitis by targeting nitric oxide and peroxynitrite: implications for the treatment of multiple sclerosis. Proc Natl Acad Sci USA 94 2528-2533.
75. DC Hooper, S Spitsin, RB Kean, et al. (1998) Uric acid, a natural scavenger of peroxynitrite in experimental allergic encephalomyelitis and multiple sclerosis. Proc Natl Acad Sci USA 95 675-680.
76. B Malfroy, SR Doctrow, PL Orr, et al. (1997) Prevention and suppression of autoimmune encephalomyelitis by EUK-8, a synthetic catalytic scavenger of oxygen-reactive metabolites. Cell Immunol 177 62-68.
77. ED Hall (1992) Novel inhibitors of iron-dependent lipid peroxidation for neurodegenerative disorders. Ann Neurol 32 S137-S142.
78. LA Hansen, DO Willenborg and WB Cowden (1995) Suppression of hyperacute and passively transferred experimental autoimmune encephalomyelitis by the antioxidant, butylated hydroxyanisole. J Neurimmunol 62 69-77.
79. AH Cross, TP Misko, RF Lin, et al. (1994) Aminoguanidine, an inhibitor of inducible nitric oxide synthase, ameliorates experimental autoimmune encephalomyelitis in SJL mice. J Clin Invest 93 2684-2690.
80. W Zhao, RG Tilton, JA Corbett, et al. (1996) Experimental allergic encephalomyelitis in the rat is inhibited by aminoguanidine, an inhibitor of nitric oxide synthase. J Neuroimmunol 64 123-133.
81. T Brenner, S Brocke, F Szafer, et al. (1997) Induction of nitric oxide synthase in for the treatment of experimental autoimmune encephalomyelitis. J Immunol 158 2940-2946.
82. M Ding, M Zhang, JL Wong, et al. (1998) Antisense knockdown of inducible nitric oxide synthase inhibits induction of experimental autoimmune encephalomyelitis in SJL/J mice. J Immunol 160 2560-2564.
83. CG Jolivalt, RB Howard, LS Chen, et al. (2003) A novel nitric oxide scavenger in combination with cyclosporine A ameliorates experimental autoimmune encephalomyelitis progression in mice. J Neuroimmunol 138 56-64.
84. A Mohamed, A Shoker, F Bendjelloul, et al. (2003) Improvement of experimental allergic encephalomyelitis (EAE) by thymoquinone; an oxidative stress inhibitor. Biomed Sci Instrum 39 440-445.
85. M Penkowa and J Hidalgo (2003) Treatment with metallothionein prevents demyelination and axonal damage and increases oligodendrocyte precursors and tissue repair during experimental autoimm. J Neurosci Res 72 574-586.
86. Y Liu, B Zhu, X Wang, et al. (2003) Bilirubin as a potent antioxidant suppresses experimental autoimmune encephalomyelitis: implications for the role of oxidative stress in the development of mu. J Neuroimmunol 139 27-35.
87. C Hutter (1993) On the causes of multiple sclerosis. Med Hypotheses 41 93-96.
88. GM Timmerman and AK Stuifbergin (1999) Eating patterns in women with multiple sclerosis. J Neurosci Nurs 31 152-158.
89. G Comi, M Filippi and JS Wolinsky (2001) European/Canadian multicenter double blind randomized placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured dis. Ann Neurol 49 290-297.
90. C Jensen and J Clausen (1986) Glutathione peroxidase activity, associated enzymes and substrates in blood cells from patients with multiple sclerosis-effects of antioxidant supplementation. Acta Pharmacol Toxicol (Copenh) 59 S450-S453.
91. V Yadav, G Marracci, J Lovera, et al. (2005) Lipoic acid in multiple sclerosis: a pilot study. Mult Scler 11 159-165.
92. DC Hewson, MA Phillips, KE Simpson, et al. (1984) Food intake in multiple sclerosis. Hum Nutr Appl Nutr 38 355-367.
93. S Spitsin, DC Hooper, T Leist, et al. (2001.) Inactivation of peroxynitrite in multiple sclerosis patients after oral administration of inosine may suggest possible approaches to therapy of the disease. Mult Scler 7 313-319.